SUBSCRIBE
SUBSCRIBE

Asia

Business
BioSpace Movers & Shakers, July 31
Biopharma and life science companies strengthen their leadership teams and board with these Movers & Shakers.
July 30, 2020
 · 
6 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: July 31
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.
July 30, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
BioSpace Global Roundup, July 30
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
July 29, 2020
 · 
5 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: July 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
July 29, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Business
AstraZeneca and Daiichi Sankyo Ink $6 Billion Cancer Pact
AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo Company for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) for multiple cancer types.
July 27, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
July 24, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: July 20-24
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
July 24, 2020
 · 
8 min read
 · 
Mark Terry
Drug Development
Research Roundup: Progress on COVID-19 Vaccines and More
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
July 23, 2020
 · 
7 min read
 · 
Mark Terry
Favipiravir showing it's potential in COVID-19 tre
Drug Development
Glenmark Pharmaceutical’s Antiviral Drug Favipiravir Hits the Mark in Small, Phase III COVID-19 Study
An antiviral drug, favipiravir, developed by Glenmark Pharmaceuticals, boosted the time it takes COVID-19 patients with mild to moderate symptoms to improve their health in a Phase III study.
July 23, 2020
 · 
2 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: July 24
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
July 23, 2020
 · 
4 min read
 · 
Editorial Staff
Load More
PRESS RELEASES
Press Releases
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
February 24, 2025
 · 
8 min read
Press Releases
NMPA Accepts NDA and Grants Priority Review Designation to Innovent’s Ipilimumab Injection, China’s First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer
February 24, 2025
 · 
10 min read
Press Releases
Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)
February 24, 2025
 · 
6 min read
Press Releases
ADDING MULTIMEDIA ReCerise Signs New Research Collaboration Agreement towards Development of Innovative Treatment for Hepatocellular Carcinoma
February 21, 2025
 · 
2 min read
Press Releases
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
February 21, 2025
 · 
5 min read
Press Releases
Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab
February 21, 2025
 · 
9 min read
Press Releases
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
February 21, 2025
 · 
12 min read
Press Releases
Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer
February 21, 2025
 · 
4 min read
Press Releases
ReCerise Signs New Research Collaboration Agreement towards Development of Innovative Treatment for Hepatocellular Carcinoma
February 21, 2025
 · 
2 min read
Press Releases
NAVER D2SF-Backed PranaQ® Receives FDA 510(k) Clearance for TipTraQ, an AI-Enabled Home Sleep Apnea Test
February 20, 2025
 · 
3 min read
Press Releases
World’s First Potential Target Therapy for Diffuse Gastric Cancer Granted Fast Track Designation by the U.S. FDA
February 20, 2025
 · 
3 min read
Press Releases
111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow
February 20, 2025
 · 
2 min read
Press Releases
Triastek D23 (Budesonide Ileum Targeted Tablets) Receives Positive Clinical Results
February 20, 2025
 · 
2 min read
Press Releases
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development
February 20, 2025
 · 
5 min read
Press Releases
NaviFUS Corp. Leverages Taiwan’s Advanced Chip Technology to Lead Non-Invasive Precision Medicine for Brain Disorders
February 20, 2025
 · 
3 min read
Press Releases
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
February 20, 2025
 · 
2 min read
Press Releases
Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics
February 20, 2025
 · 
3 min read
Press Releases
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
February 19, 2025
 · 
13 min read
Press Releases
Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
February 19, 2025
 · 
4 min read
Press Releases
HUTCHMED to Announce 2024 Final Results
February 19, 2025
 · 
1 min read
Load More